Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Response to BRAF/MEK Inhi… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma

Artikel i vetenskaplig tidskrift
Författare Sara Bjursten
Christoffer Vannas
Stefan Filges
Florian Puls
Ankur Pandita
Henrik Fagman
Anders Ståhlberg
Max Levin
Publicerad i Case Reports in Oncology
Volym 12
Nummer/häfte 3
Sidor 872-879
Publiceringsår 2019
Publicerad vid Institutionen för kliniska vetenskaper, Avdelningen för onkologi
Sahlgrenska Cancer Center
Institutionen för biomedicin, avdelningen för laboratoriemedicin
Wallenberg Centre for Molecular and Translational Medicine
Sidor 872-879
Språk en
Länkar https://doi.org/10.1159/000504291
Ämnesord BRAF A598_T599insV, Circulating cell-free tumor DNA, Melanoma, Targeted therapy
Ämneskategorier Cancer och onkologi

Sammanfattning

Approximately 50% of patients with metastatic melanoma harbor an activating BRAF mutation. Tumors with activating mutation BRAF gene proliferate excessively and can be treated with targeted BRAF-inhibitors in combination with MEK inhibitors. The most common BRAF mutation occurs at amino acid position 600. Other BRAF mutations are rare and their predictive value for treatment response to BRAF/MEK inhibition is low. Here, we report on a patient with a BRAF A598_T599insV mutated melanoma, a mutation that has only been described in one previous melanoma patient in which the treatment response to BRAF/MEK inhibition was transient. Our patient had a large ulcerated metastasis that showed a durable complete response implying that BRAF/MEK inhibition should be considered a treatment option for this mutation. We analyzed circulating cell-free tumor DNA (ctDNA) carrying the BRAF A598_T599insV mutation throughout treatment. The allele frequency of BRAF A598_T599insV decreased during regression of the tumors, indicating that this method has potential to monitor treatment response. Our case demonstrates durable response to BRAF/MEK inhibition in a melanoma patient carrying a BRAF A598_T599insV mutation. In addition, we show that allele frequency analysis of A598_T599insV mutation in blood using ultrasensitive sequencing can be used to monitor treatment response.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?